The suit says the companies sought not only to maintain their "fair share" of the generic drug market but also to "significantly raise prices on as many drugs as possible." During a 19-month period beginning in July 2013, the suit says Teva significantly raised prices on approximately 112 different generic drugs and on at least 86 of those drugs colluded with a group it referred to as "high quality" competitors. The suit says that the size of the price increases varied but was over 1,000% for a number of the drugs.